Annual report
9273.TEDINET S100P8UB
Period2021-07-01 → 2022-06-30
Filed2022-09-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥20.4bn | 2021-07-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥17.8bn | 2020-07-01 → 2021-06-30 | Cons. | Net sales |
| Revenue | ¥16.0bn | 2019-07-01 → 2020-06-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥15.2bn | 2018-07-01 → 2019-06-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥14.8bn | 2017-07-01 → 2018-06-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥3.8bn | 2021-07-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥3.4bn | 2020-07-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥3.8bn | 2021-07-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.4bn | 2020-07-01 → 2021-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.4bn | 2019-07-01 → 2020-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2018-07-01 → 2019-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2017-07-01 → 2018-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.8bn | 2021-07-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.4bn | 2020-07-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.4bn | 2021-07-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.1bn | 2020-07-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.7bn | 2019-07-01 → 2020-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥654m | 2018-07-01 → 2019-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥735m | 2017-07-01 → 2018-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.4bn | 2021-07-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2020-07-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥26.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥24.8bn | at 2021-06-30 | Cons. | Assets |
| Total assets | ¥22.9bn | at 2020-06-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥22.1bn | at 2019-06-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥21.6bn | at 2018-06-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.6bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥8.1bn | at 2021-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥18.7bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥16.7bn | at 2021-06-30 | Cons. | Net assets |
| Net assets / equity | ¥14.9bn | at 2020-06-30d | Cons. | Net assets |
| Net assets / equity | ¥13.4bn | at 2019-06-30d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥13.0bn | at 2018-06-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.1bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥8.3bn | at 2021-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥8.4bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.6bn | at 2021-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.4bn | at 2020-06-30d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.3bn | at 2019-06-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.9bn | at 2018-06-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.1bn | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.1bn | 2020-07-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.3bn | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥385m | 2018-07-01 → 2019-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.2bn | 2017-07-01 → 2018-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥477m | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥223m | 2020-07-01 → 2021-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥547m | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥244m | 2018-07-01 → 2019-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥867m | 2017-07-01 → 2018-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥805m | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥679m | 2020-07-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥557m | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥816m | 2018-07-01 → 2019-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥969m | 2017-07-01 → 2018-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥59.55 | 2021-07-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.94 | 2020-07-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.05 | 2019-07-01 → 2020-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥16.5 | 2018-07-01 → 2019-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.59 | 2017-07-01 → 2018-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥471.14 | at 2022-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥421.61 | at 2021-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥376.48 | at 2020-06-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥338.45 | at 2019-06-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥327.77 | at 2018-06-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 71.1% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.3% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.1% | at 2020-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.7% | at 2019-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.1% | at 2018-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 13.3% | 2021-07-01 → 2022-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.5% | 2020-07-01 → 2021-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.3% | 2019-07-01 → 2020-06-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2018-07-01 → 2019-06-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.9% | 2017-07-01 → 2018-06-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 303 | at 2022-06-30 | Cons. | Number of employees |
| Employees | 303 | at 2021-06-30 | Cons. | Number of employees |
| Employees | 296 | at 2020-06-30d | Cons. | Number of employees |
| Employees | 310 | at 2019-06-30d | Cons. | Number of employees |
| Employees | 308 | at 2018-06-30d | Cons. | Number of employees |
| Revenue | ¥704m | 2021-07-01 → 2022-06-30 | Standalone | Operating revenue1 |
| Revenue | ¥638m | 2020-07-01 → 2021-06-30 | Standalone | Operating revenue1 |
| Revenue | ¥628m | 2019-07-01 → 2020-06-30d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥2.1bn | 2018-07-01 → 2019-06-30d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥557m | 2017-07-01 → 2018-06-30d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥86m | 2021-07-01 → 2022-06-30 | Standalone | Operating income |
| Operating income | ¥74m | 2020-07-01 → 2021-06-30 | Standalone | Operating income |
| Ordinary income | ¥89m | 2021-07-01 → 2022-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥78m | 2020-07-01 → 2021-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥142m | 2019-07-01 → 2020-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.6bn | 2018-07-01 → 2019-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥120m | 2017-07-01 → 2018-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥89m | 2021-07-01 → 2022-06-30 | Standalone | Income before income taxes |
| Profit before tax | ¥78m | 2020-07-01 → 2021-06-30 | Standalone | Income before income taxes |
| Net income | ¥95m | 2021-07-01 → 2022-06-30 | Standalone | Profit loss |
| Net income | ¥76m | 2020-07-01 → 2021-06-30 | Standalone | Profit loss |
| Net income | ¥160m | 2019-07-01 → 2020-06-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.5bn | 2018-07-01 → 2019-06-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥115m | 2017-07-01 → 2018-06-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥11.9bn | at 2022-06-30 | Standalone | Assets |
| Total assets | ¥12.1bn | at 2021-06-30 | Standalone | Assets |
| Total assets | ¥12.1bn | at 2020-06-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.9bn | at 2019-06-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.0bn | at 2018-06-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.7bn | at 2022-06-30 | Standalone | Liabilities |
| Total liabilities | ¥1.6bn | at 2021-06-30 | Standalone | Liabilities |
| Net assets / equity | ¥10.3bn | at 2022-06-30 | Standalone | Net assets |
| Net assets / equity | ¥10.6bn | at 2021-06-30 | Standalone | Net assets |
| Net assets / equity | ¥10.8bn | at 2020-06-30d | Standalone | Net assets |
| Net assets / equity | ¥10.9bn | at 2019-06-30d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥9.6bn | at 2018-06-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥842m | at 2022-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2021-06-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥2.41 | 2021-07-01 → 2022-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1.93 | 2020-07-01 → 2021-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥4.04 | 2019-07-01 → 2020-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.94 | 2018-07-01 → 2019-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥3.06 | 2017-07-01 → 2018-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥11 | 2021-07-01 → 2022-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥10 | 2020-07-01 → 2021-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥34 | 2019-07-01 → 2020-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2018-07-01 → 2019-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2017-07-01 → 2018-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥258.89 | at 2022-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥266.48 | at 2021-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥273.06 | at 2020-06-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥275.02 | at 2019-06-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥242.92 | at 2018-06-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 85.9% | at 2022-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.0% | at 2021-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2020-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.4% | at 2019-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.7% | at 2018-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 0.9% | 2021-07-01 → 2022-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.7% | 2020-07-01 → 2021-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.5% | 2019-07-01 → 2020-06-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.6% | 2018-07-01 → 2019-06-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.2% | 2017-07-01 → 2018-06-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 39,619,980 | at 2022-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 39,619,980 | at 2021-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,904,995 | at 2020-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,904,995 | at 2019-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,301,665 | at 2018-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 22 | at 2022-06-30 | Standalone | Number of employees |
| Employees | 22 | at 2021-06-30 | Standalone | Number of employees |
| Employees | 20 | at 2020-06-30d | Standalone | Number of employees |
| Employees | 17 | at 2019-06-30d | Standalone | Number of employees |
| Employees | 18 | at 2018-06-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 55
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-07-01 → 2022-06-30 | ¥322,000 |
| Reconciling Itemsreconciling | depreciation | 2021-07-01 → 2022-06-30 | ¥5m |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2022-06-30 | −¥1.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2022-06-30 | −¥1.9bn |
| Reconciling Itemsreconciling | segment assets | at 2022-06-30 | ¥108m |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2022-06-30 | −¥4m |
| Drug Substance Sales Businessreportable segment | capex | 2021-07-01 → 2022-06-30 | ¥34m |
| Drug Substance Sales Businessreportable segment | depreciation | 2021-07-01 → 2022-06-30 | ¥92m |
| Drug Substance Sales Businessreportable segment | employees | at 2022-06-30 | 77 pure |
| Drug Substance Sales Businessreportable segment | revenue | 2021-07-01 → 2022-06-30 | ¥14.7bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2021-07-01 → 2022-06-30 | ¥12.8bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2021-07-01 → 2022-06-30 | ¥1.9bn |
| Drug Substance Sales Businessreportable segment | segment assets | at 2022-06-30 | ¥15.4bn |
| Drug Substance Sales Businessreportable segment | segment profit | 2021-07-01 → 2022-06-30 | ¥2.4bn |
| Pharmaceutical Marketing Businessreportable segment | capex | 2021-07-01 → 2022-06-30 | ¥353m |
| Pharmaceutical Marketing Businessreportable segment | depreciation | 2021-07-01 → 2022-06-30 | ¥582m |
| Pharmaceutical Marketing Businessreportable segment | employees | at 2022-06-30 | 204 pure |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2021-07-01 → 2022-06-30 | ¥7.5bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2021-07-01 → 2022-06-30 | ¥7.5bn |
| Pharmaceutical Marketing Businessreportable segment | segment assets | at 2022-06-30 | ¥10.7bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2021-07-01 → 2022-06-30 | ¥1.4bn |
| —segment total | capex | 2021-07-01 → 2022-06-30 | ¥387m |
| —segment total | depreciation | 2021-07-01 → 2022-06-30 | ¥674m |
| —segment total | employees | at 2022-06-30 | 281 pure |
| —segment total | revenue | 2021-07-01 → 2022-06-30 | ¥22.2bn |
| —segment total | revenue external | 2021-07-01 → 2022-06-30 | ¥20.4bn |
| —segment total | revenue intersegment | 2021-07-01 → 2022-06-30 | ¥1.9bn |
| —segment total | segment assets | at 2022-06-30 | ¥26.1bn |
| —segment total | segment profit | 2021-07-01 → 2022-06-30 | ¥3.8bn |
| Reconciling Itemsreconciling | capex | 2020-07-01 → 2021-06-30 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2020-07-01 → 2021-06-30 | ¥5m |
| Reconciling Itemsreconciling | revenue | 2020-07-01 → 2021-06-30 | −¥1.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2020-07-01 → 2021-06-30 | −¥1.7bn |
| Reconciling Itemsreconciling | segment assets | at 2021-06-30 | ¥344m |
| Reconciling Itemsreconciling | segment profit | 2020-07-01 → 2021-06-30 | −¥65m |
| Drug Substance Sales Businessreportable segment | capex | 2020-07-01 → 2021-06-30 | ¥62m |
| Drug Substance Sales Businessreportable segment | depreciation | 2020-07-01 → 2021-06-30 | ¥85m |
| Drug Substance Sales Businessreportable segment | revenue | 2020-07-01 → 2021-06-30 | ¥12.5bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2020-07-01 → 2021-06-30 | ¥10.8bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2020-07-01 → 2021-06-30 | ¥1.7bn |
| Drug Substance Sales Businessreportable segment | segment assets | at 2021-06-30 | ¥14.3bn |
| Drug Substance Sales Businessreportable segment | segment profit | 2020-07-01 → 2021-06-30 | ¥2.2bn |
| Pharmaceutical Marketing Businessreportable segment | capex | 2020-07-01 → 2021-06-30 | ¥271m |
| Pharmaceutical Marketing Businessreportable segment | depreciation | 2020-07-01 → 2021-06-30 | ¥536m |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2020-07-01 → 2021-06-30 | ¥7.0bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2020-07-01 → 2021-06-30 | ¥7.0bn |
| Pharmaceutical Marketing Businessreportable segment | segment assets | at 2021-06-30 | ¥10.1bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2020-07-01 → 2021-06-30 | ¥1.2bn |
| —segment total | capex | 2020-07-01 → 2021-06-30 | ¥334m |
| —segment total | depreciation | 2020-07-01 → 2021-06-30 | ¥621m |
| —segment total | revenue | 2020-07-01 → 2021-06-30 | ¥19.5bn |
| —segment total | revenue external | 2020-07-01 → 2021-06-30 | ¥17.8bn |
| —segment total | revenue intersegment | 2020-07-01 → 2021-06-30 | ¥1.7bn |
| —segment total | segment assets | at 2021-06-30 | ¥24.5bn |
| —segment total | segment profit | 2020-07-01 → 2021-06-30 | ¥3.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,298
| Item | Context | Value | Unit |
|---|---|---|---|
| Other net inv cf | CurrentYearDuration | -3809000 | JPY |
| Net cash provided by used in investment activities | Prior1YearDuration | -223286000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration | -477331000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YearDuration | -321332000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -383248000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -336573000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -395443000 | JPY |
| Purchase of treasury stock fin cf | Prior1YearDuration | -70000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | -31000 | JPY |
| Other net fin cf | Prior1YearDuration | -20576000 | JPY |
| Other net fin cf | CurrentYearDuration | -26211000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -678551000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -804934000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | 10164000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | 19819000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 2159705000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | 831739000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 5430414000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 7590119000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 7590119000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 8421859000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 4 | |
| Write downs of inventories | Prior1YearDuration | 153667000 | JPY |
| Write downs of inventories | CurrentYearDuration | 26404000 | JPY |
| Directors compensations sga | Prior1YearDuration | 217502000 | JPY |
| Directors compensations sga | CurrentYearDuration | 223875000 | JPY |
| Salaries and allowances sga | Prior1YearDuration | 570151000 | JPY |
| Salaries and allowances sga | CurrentYearDuration | 553398000 | JPY |
| Retirement benefit expenses sga | Prior1YearDuration | 19409000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | 18163000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YearDuration | -526000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYearDuration | － | JPY |
| Provision for bonuses sga | Prior1YearDuration | 40316000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 37552000 | JPY |
| Provision for directors retirement benefits sga | Prior1YearDuration | 12695000 | JPY |
| Provision for directors retirement benefits sga | CurrentYearDuration | 13705000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 124798000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 83377000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 10794690000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 7021386000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 17816077000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 17816077000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 1709590000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | 1709590000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | -1709590000 | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 12504281000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 7021386000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |